A Meta-analysis on lipid-regulation effect of Xuezhikang in patients with coronary heart disease complicating hyperlipemia

LI Yin-hua; JIA Zhang-rong; JIANG Long; YANG Qiu; WANG Lv-ya

doi:10.3969/j.1674-4055.2014.01.07

Abstract：Objective To review the lipid-regulation effect of Xuezhikang in patients with coronary heart disease (CHD) complicating hyperlipemia. Methods The databases of PubMed, Cochrane Library, EBSCO host, CNKI, WangFang Database and Vip Database were retrieved with computer until to Oct. 2013. The randomized controlled trials (RCT) were collected and read and extracted by two independent researches. The data was given a Meta-analysis by using Revman 5.2 software. The influences of Xuezhikang on the levels of cholesterol (TC), triglyceride (TG), low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) were reviewed systematically. Results There were totally 19 RCT included involving 6229 cases. The Meta-analysis showed that on the base of CHD routine treatment, the levels of TC, TG and LDL-C decreased significantly [(WMD=-1.15, 95%CI:-1.67~-0.64, P<0.001), (WMD=-0.51, 95%CI:-0.83~-0.20, P=0.002), (WMD=-0.99, 95%CI: -1.38~-0.59, P<0.001)], and HDL-C level increased significantly (WMD=0.21, 95%CI: 0.05~0.38, P=0.01) in Xuezhikang group compared with placebo group. The levels of TC, TG and LDL-C decreased significantly [(WMD=-1.19, 95%CI:-1.45~-0.93, P<0.001), (WMD=-1.19, 95%CI:-1.45~-0.93, P<0.001), (WMD=-1.00, 95%CI:-1.27~-0.73, P<0.001)], and HDL-C level increased significantly (WMD=0.17, 95%CI:0.05~0.29, P=0.007) in Xuezhikang group compared with routine treatment group. The levels of TC, TG, LDL-C and HDL-C had no statistical significance between Xuezhikang and statins. Conclusion On the base of CHD routine treatment, Xuezhikang can regulate blood fat effectively and its effect is similar to that of statins.